GlassScriptPhysician profile
Christopher J Superczynski
NPI 1184621138
$9,130.25
in general payments reported to CMS, 2019-2025
47 companies · $2,101 in 2025
The $2,101 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $426 · 2020: $429 · 2021: $1,046 · 2022: $1,641 · 2023: $1,708 · 2024: $1,779 · 2025: $2,101.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,588.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,588.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,207.41 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Pfizer INC. | $1,190.48 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $715.68 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $653.63 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $478.40 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $455.65 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Abbott Laboratories | $409.44 | 2021-2025 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $326.73 | 2019-2022 | |
| Astellas Pharma US INC | $300.74 | 2019-2023 | Veozah, Myrbetriq |
| Janssen Pharmaceuticals, INC | $298.45 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $233.95 | 2019-2025 | Eliquis |
| Mylan Specialty L.P. | $219.55 | 2019-2024 | Yupelri |
| Phathom Pharmaceuticals, INC. | $212.10 | 2024-2025 | Voquezna |
| Tolmar, INC. | $196.00 | 2023-2025 | Jatenzo |
| Lundbeck LLC | $194.52 | 2023-2025 | Rexulti |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $152.06 | 2023-2025 | Gemtesa |
| Exact Sciences Corporation | $148.78 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Orexo US, INC. | $133.97 | 2020-2024 | Zubsolv |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $133.64 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $132.52 | 2019-2023 | Spiriva Respimat, Stiolto Respimat |
| Indivior INC. | $108.48 | 2019-2025 | Sublocade |
| Dexcom, INC. | $96.76 | 2024 | Dexcom G6 Transmitter |
| Axsome Therapeutics, INC. | $95.45 | 2023-2024 | Sunosi |
| Sunovion Pharmaceuticals INC. | $92.78 | 2022 | |
| Halozyme INC | $68.98 | 2023 | |
| Novartis Pharmaceuticals Corporation | $64.63 | 2021-2024 | |
| Acerus Pharmaceuticals Corporation | $60.79 | 2021-2022 | |
| Antares Pharma, INC. | $60.00 | 2020-2023 | Nocdurna, Xyosted, Tlando |
| Corcept Therapeutics | $59.97 | 2024-2025 | Korlym |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $57.88 | 2025 | Caplyta |
| Allergan, INC. | $53.33 | 2019-2022 | |
| Amgen INC. | $48.88 | 2023-2024 | Repatha |
| Corium, LLC | $47.75 | 2023 | Azstarys |
| Merck Sharp & Dohme LLC | $42.18 | 2019-2023 | Verquvo, Steglatro, Belsomra |
| Covis Pharma Gmbh | $41.62 | 2021 | |
| Idorsia Pharmaceuticals US INC | $39.12 | 2023-2024 | Quviviq |
| Braeburn INC. | $39.01 | 2025 | Brixadi |
| Viatris Specialty LLC | $37.33 | 2025 | Yupelri |
| Ibsa Pharma INC. | $34.76 | 2022 | |
| Verity Pharmaceuticals INC. | $32.21 | 2024 | Tlando |
| Verona Pharma, INC. | $30.24 | 2025 | Ohtuvayre |
| Scilex Pharmaceuticals INC. | $23.85 | 2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $22.86 | 2022 | |
| Hikma Pharmaceuticals USA | $22.80 | 2022 | |
| Almatica Pharma LLC | $22.34 | 2022 | |
| Shield Therapeutics INC | $16.55 | 2024 | |
| Currax Pharmaceuticals LLC | $16.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Superczynski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.